NCT01993680View on ClinicalTrials.gov

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 1, 2016

Conditions

Autonomic Disturbances in Parkinson's Disease

Interventions

DRUG

Pyridostigmine bromide

"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"

DRUG

fludrocortisone

drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days

Trial Locations (1)

8091

University Hospital Zurich, Division of Neurology, Zurich

All Listed Sponsors

lead

Christian Baumann

OTHER

NCT01993680 - Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment | Biotech Hunter | Biotech Hunter